SEC Comment Letter 0000000000-23-013218 to Acrivon Therapeutics, Inc. (ACRV) (CIK 0001781174) (ACRV)
Acrivon Therapeutics, Inc. (ACRV) (CIK 0001781174)
Date: Dec. 5, 2023 · CIK: 0001781174 · Accession: 0000000000-23-013218
AI Filing Summary & Sentiment
File numbers found in text: 333-275854
Letter
United States securities and exchange commission logo December 5, 2023 Rasmus Holm-Jorgensen Chief Financial Officer Acrivon Therapeutics, Inc. 480 Arsenal Way, Suite 100 Watertown, Massachusetts 02472 Re:Acrivon Therapeutics, Inc. Registration Statement on Form S-3 Filed December 1, 2023 File No. 333-275854 Dear Rasmus Holm-Jorgensen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Archer Rubin
Show Raw Text
United States securities and exchange commission logo
December 5, 2023
Rasmus Holm-Jorgensen
Chief Financial Officer
Acrivon Therapeutics, Inc.
480 Arsenal Way, Suite 100
Watertown, Massachusetts 02472
Re:Acrivon Therapeutics, Inc.
Registration Statement on Form S-3
Filed December 1, 2023
File No. 333-275854
Dear Rasmus Holm-Jorgensen:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Archer Rubin